Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
As mortgage rates have begun to approach 6.0%, refinancing applications are on the rise in February 2025. They've surged 132% from one year ago, according to the Mortgage Bankers Association's weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results